CAMBRIDGE, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Targanta Therapeutics Corporation today announced its participation in the Lazard Capital Markets Fourth Annual Healthcare Conference, taking place November 27 and 28, 2007 at the New York Palace Hotel in New York City. Mark Leuchtenberger, President and Chief Executive Officer of Targanta, will be presenting at 2:00 pm ET on Tuesday, November 27, 2007.
The audio portion of the presentation will be webcast live and the replay available for 30 days via http://www.wsw.com/webcast/lz4/targ/, or through the Investor Relations section of Targanta’s website at www.targanta.com/investors.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company’s pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, Canada and Toronto, Ontario, Canada. To find out more about Targanta , visit our website at www.targanta.com.
CONTACT: Investors: George Eldridge, Senior Vice President Finance &
Administration and Chief Financial Officer of Targanta Therapeutics
Corporation, +1-617-577-9020, ext. 212; or Financial Media: Brian Ritchie
of Financial Dynamics for Targanta Therapeutics Corporation,
+1-212-850-5683
Web site: http://www.wsw.com/webcast/lz4/targ/
http://www.targanta.com/investors/
http://www.targanta.com/
